uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 13, 2023...
uniQure to Participate in Multiple Upcoming Industry Conferences in March LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 02, 2023...
uniQure Announces 2022 Financial Results and Highlights Recent Company Progress ~ Achieved U.S. and European Commission marketing approvals...
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of...
uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B ~ Historic approval represents the...
uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations...
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LEXINGTON, Mass. and AMSTERDAM, Dec. 20, 2022 (GLOBE NEWSWIRE...
uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia B If approved, etranacogene...
uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event ~...
uniQure announces FDA approval of first gene therapy for adults with hemophilia B ~ Historic approval provides a new treatment option that...
uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022 ~ Event to be Webcast Live on uniQure’s Corporate...
uniQure Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress ~ Patient enrollment at the higher dose of...
uniQure Announces Multiple Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT) Eight...
uniQure to Participate in Upcoming Industry Conferences in October LEXINGTON, Mass. and AMSTERDAM, Oct. 03, 2022 (GLOBE NEWSWIRE...
uniQure to Participate in Upcoming Industry Conferences in September LEXINGTON, Mass. and AMSTERDAM, Sept. 06, 2022 (GLOBE NEWSWIRE...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads